Compare Davita Inc (DVA) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Lemonade Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Lemonade Inc trades at $53.08 (market cap $4.08B). The key difference: Davita Inc is far larger — about 2.9× Lemonade Inc's market cap, and Davita Inc is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| DVA | LMND | |
|---|---|---|
Market Cap | $11.72B | $4.08B |
Sector | Health | Financials |
52-Week High | $240.96 | $96.57 |
52-Week Low | $103.87 | $47.38 |
Enterprise Value | $24.44B | $3.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Lemonade (LMND) trades at $52.94, up 2.08% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue growth is strong at 79% year-over-year in Q2 2026, but profitability remains elusive with a net income margin of -14.19% in 2025. The company targets positive adjusted EBITDA by Q4 2026, supported by expanding insurance offerings in states like Nebraska and Maine.
The outlook is mixed: accelerating premium growth and path to profitability offer upside, but high valuation (P/S of 4.11) and persistent losses pose risks. Analyst consensus is evenly split, with a $58 price target suggesting modest upside from current levels, though technical resistance near $54 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
